<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Vogrig A</submitter><funding>LABEX CORTEX</funding><funding>BETPSY</funding><funding>Fondation pour la recherche médicale</funding><funding>French National Research Agency</funding><pagination>fcab185</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8453430</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>3(3)</volume><pubmed_abstract>In this study, we report the clinical features of Kelch-like protein 11 antibody-associated paraneoplastic neurological syndrome, design and validate a clinical score to facilitate the identification of patients that should be tested for Kelch-like protein 11 antibodies, and examine in detail the nature of the immune response in both the brain and the tumour samples for a better characterization of the immunopathogenesis of this condition. The presence of Kelch-like protein 11 antibodies was retrospectively assessed in patients referred to the French Reference Center for paraneoplastic neurological syndrome and autoimmune encephalitis with (i) antibody-negative paraneoplastic neurological syndrome [limbic encephalitis (&lt;i>n&lt;/i> = 105), cerebellar degeneration (&lt;i>n&lt;/i> = 33)] and (ii) antibody-positive paraneoplastic neurological syndrome [Ma2-Ab encephalitis (&lt;i>n&lt;/i> = 34), antibodies targeting N-methyl-D-aspartate receptor encephalitis with teratoma (&lt;i>n&lt;/i> = 49)]. Additionally, since 1 January 2020, patients were prospectively screened for Kelch-like protein 11 antibodies as new usual clinical practice. Overall, Kelch-like protein 11 antibodies were detected in 11 patients [11/11, 100% were male; their median (range) age was 44 (35-79) years], 9 of them from the antibody-negative paraneoplastic neurological syndrome cohort, 1 from the antibody-positive (Ma2-Ab) cohort and 1 additional prospectively detected patient. All patients manifested a cerebellar syndrome, either isolated (4/11, 36%) or part of a multi-system neurological disorder (7/11, 64%). Additional core syndromes were limbic encephalitis (5/11, 45%) and myelitis (2/11, 18%). Severe weight loss (7/11, 64%) and hearing loss/tinnitus (5/11, 45%) were common. Rarer neurologic manifestations included hypersomnia and seizures (2/11, 18%). Two patients presented phenotypes resembling primary neurodegenerative disorders (progressive supranuclear palsy and flail arm syndrome, respectively). An associated cancer was found in 9/11 (82%) patients; it was most commonly (7/9, 78%) a spontaneously regressed ('burned-out') testicular germ cell tumour. A newly designed clinical score (MATCH score: male, ataxia, testicular cancer, hearing alterations) with a cut-off ≥4 successfully identified patients with Kelch-like protein 11 antibodies (sensitivity 78%, specificity 99%). Pathological findings (three testicular tumours, three lymph node metastases of testicular tumours, one brain biopsy) showed the presence of a T-cell inflammation with resulting anti-tumour immunity in the testis and one chronic, exhausted immune response-demonstrated by immune checkpoint expression-in the metastases and the brain. In conclusion, these findings suggest that Kelch-like protein 11 antibody paraneoplastic neurological syndrome is a homogeneous clinical syndrome and its detection can be facilitated using the MATCH score. The pathogenesis is probably T-cell mediated, but the stages of inflammation are different in the testis, metastases and the brain.</pubmed_abstract><journal>Brain communications</journal><pubmed_title>Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis.</pubmed_title><pmcid>PMC8453430</pmcid><funding_grant_id>ANR-11-LABX-0042</funding_grant_id><funding_grant_id>ANR-18-RHUS-0012</funding_grant_id><funding_grant_id>DQ20170336751</funding_grant_id><pubmed_authors>Benaiteau M</pubmed_authors><pubmed_authors>Montcuquet A</pubmed_authors><pubmed_authors>Bachoumas P</pubmed_authors><pubmed_authors>Honnorat J</pubmed_authors><pubmed_authors>Salhi H</pubmed_authors><pubmed_authors>Pinto AL</pubmed_authors><pubmed_authors>Mittelbronn M</pubmed_authors><pubmed_authors>Montaut S</pubmed_authors><pubmed_authors>Muniz-Castrillo S</pubmed_authors><pubmed_authors>Vogrig A</pubmed_authors><pubmed_authors>Letovanec I</pubmed_authors><pubmed_authors>Michenet P</pubmed_authors><pubmed_authors>Lanoiselee HM</pubmed_authors><pubmed_authors>Picard G</pubmed_authors><pubmed_authors>Uro-Coste E</pubmed_authors><pubmed_authors>Rogemond V</pubmed_authors><pubmed_authors>Pericart S</pubmed_authors><pubmed_authors>Zephir H</pubmed_authors><pubmed_authors>Selton M</pubmed_authors><pubmed_authors>Pariente J</pubmed_authors><pubmed_authors>Giordana C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis.</name><description>In this study, we report the clinical features of Kelch-like protein 11 antibody-associated paraneoplastic neurological syndrome, design and validate a clinical score to facilitate the identification of patients that should be tested for Kelch-like protein 11 antibodies, and examine in detail the nature of the immune response in both the brain and the tumour samples for a better characterization of the immunopathogenesis of this condition. The presence of Kelch-like protein 11 antibodies was retrospectively assessed in patients referred to the French Reference Center for paraneoplastic neurological syndrome and autoimmune encephalitis with (i) antibody-negative paraneoplastic neurological syndrome [limbic encephalitis (&lt;i>n&lt;/i> = 105), cerebellar degeneration (&lt;i>n&lt;/i> = 33)] and (ii) antibody-positive paraneoplastic neurological syndrome [Ma2-Ab encephalitis (&lt;i>n&lt;/i> = 34), antibodies targeting N-methyl-D-aspartate receptor encephalitis with teratoma (&lt;i>n&lt;/i> = 49)]. Additionally, since 1 January 2020, patients were prospectively screened for Kelch-like protein 11 antibodies as new usual clinical practice. Overall, Kelch-like protein 11 antibodies were detected in 11 patients [11/11, 100% were male; their median (range) age was 44 (35-79) years], 9 of them from the antibody-negative paraneoplastic neurological syndrome cohort, 1 from the antibody-positive (Ma2-Ab) cohort and 1 additional prospectively detected patient. All patients manifested a cerebellar syndrome, either isolated (4/11, 36%) or part of a multi-system neurological disorder (7/11, 64%). Additional core syndromes were limbic encephalitis (5/11, 45%) and myelitis (2/11, 18%). Severe weight loss (7/11, 64%) and hearing loss/tinnitus (5/11, 45%) were common. Rarer neurologic manifestations included hypersomnia and seizures (2/11, 18%). Two patients presented phenotypes resembling primary neurodegenerative disorders (progressive supranuclear palsy and flail arm syndrome, respectively). An associated cancer was found in 9/11 (82%) patients; it was most commonly (7/9, 78%) a spontaneously regressed ('burned-out') testicular germ cell tumour. A newly designed clinical score (MATCH score: male, ataxia, testicular cancer, hearing alterations) with a cut-off ≥4 successfully identified patients with Kelch-like protein 11 antibodies (sensitivity 78%, specificity 99%). Pathological findings (three testicular tumours, three lymph node metastases of testicular tumours, one brain biopsy) showed the presence of a T-cell inflammation with resulting anti-tumour immunity in the testis and one chronic, exhausted immune response-demonstrated by immune checkpoint expression-in the metastases and the brain. In conclusion, these findings suggest that Kelch-like protein 11 antibody paraneoplastic neurological syndrome is a homogeneous clinical syndrome and its detection can be facilitated using the MATCH score. The pathogenesis is probably T-cell mediated, but the stages of inflammation are different in the testis, metastases and the brain.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2024-02-15T07:09:43.286Z</modification><creation>2022-02-11T11:15:32.522Z</creation></dates><accession>S-EPMC8453430</accession><cross_references><pubmed>34557666</pubmed><doi>10.1093/braincomms/fcab185</doi></cross_references></HashMap>